Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

INCY

Incyte Corp.

Dec 06 • 04:00PM ET

55.42

Dollar change +0.60
Percentage change 1.09	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	S&P 500	P/E	29.45	EPS (ttm)	1.88	Insider Own	1.07%	Shs Outstand	222.75M	Perf Week	3.80%
Market Cap	12.42B	Forward P/E	13.38	EPS next Y	4.14	Insider Trans	-1.23%	Shs Float	221.72M	Perf Month	1.56%
Income	424.98M	PEG	1.96	EPS next Q	1.07	Inst Own	96.61%	Short Float / Ratio	4.18% / 5.20	Perf Quarter	-12.66%
Sales	3.61B	P/S	3.44	EPS this Y	131.01%	Inst Trans	0.59%	Short Interest	9.26M	Perf Half Y	-9.72%
Book/sh	22.01	P/B	2.52	EPS next Y	17.97%	ROA	7.14%	Target Price	75.37	Perf Year	-34.09%
Cash/sh	15.69	P/C	3.53	EPS next 5Y	15.00%	ROE	9.28%	52W Range	50.27 - 86.29	Perf YTD	-31.00%
Dividend	-	P/FCF	21.38	EPS past 5Y	-	ROI	8.57%	52W High	-35.77%	Beta	0.73
Dividend %	-	Quick Ratio	3.86	Sales past 5Y	17.28%	Gross Margin	91.65%	52W Low	10.24%	ATR	1.24
Employees	2324	Current Ratio	3.91	Sales Q/Q	11.63%	Oper. Margin	14.96%	RSI (14)	55.99	Volatility	2.01% 2.12%
Optionable	Yes	Debt/Eq	0.01	EPS Q/Q	50.53%	Profit Margin	11.78%	Rel Volume	0.75	Prev Close	54.82
Shortable	Yes	LT Debt/Eq	0.01	Earnings	Oct 31 BMO	Payout	0.00%	Avg Volume	1.78M	Price	55.42
Recom	2.05	SMA20	2.93%	SMA50	0.22%	SMA200	-13.39%	Volume	1,358,151	Change	1.09%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-04-23	Upgrade	Guggenheim	Neutral → Buy	$86
Nov-21-23	Downgrade	Goldman	Buy → Neutral	$98 → $65
Jul-25-23	Initiated	Citigroup	Buy	$82
May-04-23	Downgrade	BofA Securities	Buy → Neutral	$84
Apr-10-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$81 → $79
Mar-24-23	Upgrade	SVB Securities	Underperform → Market Perform	$61
Jan-31-23	Initiated	Piper Sandler	Overweight	$100
Aug-03-22	Downgrade	Guggenheim	Buy → Neutral
Aug-03-22	Downgrade	Evercore ISI	Outperform → In-line	$90 → $78
Jul-28-22	Initiated	Wells Fargo	Equal Weight	$76
Feb-09-22	Downgrade	SVB Leerink	Mkt Perform → Underperform	$60 → $56
Jan-18-22	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$78 → $90
Nov-19-21	Initiated	BMO Capital Markets	Market Perform	$75
Jul-20-21	Upgrade	The Benchmark Company	Hold → Buy	$89
Feb-10-21	Downgrade	SVB Leerink	Mkt Perform → Underperform	$70
Jan-07-21	Initiated	Truist	Buy	$120
Jan-04-21	Upgrade	Guggenheim	Neutral → Buy
Jun-16-20	Initiated	The Benchmark Company	Hold
May-06-20	Downgrade	JP Morgan	Overweight → Neutral	$89 → $99
Apr-29-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$94

Show Previous Ratings

Dec-05-23 10:32AM	Incyte's Bullish Outlook: A Surprising Strength You Shouldn't Overlook (GuruFocus.com)
Nov-30-23 11:31AM	Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report? (Zacks)
Nov-16-23 12:17PM	5 Best Debt Free Stocks To Buy (Insider Monkey)
Nov-13-23 09:50PM	Jim Simons Stock Portfolio: 12 Biggest Healthcare Stocks (Insider Monkey)
Nov-12-23 08:18AM	3 Biotech Stocks That Are Poised to Have Breakthroughs in 2024 (InvestorPlace)
10:01PM	Loading…
Nov-09-23 10:01PM	7 Underappreciated Biotech Stocks to Pick Up on the Cheap (InvestorPlace)
Nov-02-23 09:00AM	Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting (Business Wire)
Nov-01-23 12:32PM	Incyte Corporation (NASDAQ:INCY) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-31-23 09:52PM	Analyst Report: Incyte Corporation (Morningstar Research)
12:14PM	Incyte (INCY) Beats on Q3 Earnings, Misses Revenue Estimates (Zacks)
09:36AM	Drugmaker Incyte's quarterly profit beats on lower costs (Reuters)
09:30AM	Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
08:43AM	Incyte Corp (INCY) Reports 12% Y/Y Increase in Q3'23 Total Revenues (GuruFocus.com)
08:15AM	Incyte (INCY) Surpasses Q3 Earnings Estimates (Zacks)
07:09AM	Incyte: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Loading…
07:00AM	Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs (Business Wire)
Oct-30-23 11:37AM	Drug, Biotech Stocks' Q3 Earnings Due on Oct 31: AMGN, PFE, INCY (Zacks)
Oct-27-23 11:36AM	Incyte (INCY) to Report Q3 Earnings: What's in the Cards? (Zacks)
08:00AM	Science Magazine Recognizes Incyte as #2 "Top Employer" of 2023 (Business Wire)
Oct-25-23 10:02AM	Sarepta Therapeutics (SRPT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-20-23 12:04PM	5 Cheap Biotech Stocks Smart Investors Are Piling Into (Insider Monkey)
Oct-18-23 08:00AM	Incyte to Present at Upcoming Investor Conferences (Business Wire)
Oct-16-23 08:00AM	Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023 (Business Wire)
07:30AM	Knight Therapeutics Announces CMED Price Approval of Minjuvi (tafasitamab) in Brazil (GlobeNewswire)
Oct-13-23 12:44PM	Incyte (INCY) Stock Plummets 29.6% Year to Date: Here's Why (Zacks)
10:30AM	Incyte Announces New Data for Ruxolitinib Cream (Opzelura) in Children with Atopic Dermatitis (Business Wire)
08:00AM	Data From Incytes Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) (Business Wire)
Oct-12-23 11:29AM	Incyte (INCY) Posts Upbeat Data From Phase II Vitiligo Study (Zacks)
09:00AM	Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032 (GlobeNewswire)
Oct-11-23 10:30AM	New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients (Business Wire)
09:15AM	Loading…
09:15AM	Incyte and Mandy Moore Partner to Empower People with Atopic Dermatitis to Find Their Moments of Clarity (Business Wire)
08:15AM	Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo (Business Wire)
Oct-10-23 04:45PM	Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil (GlobeNewswire)
08:00AM	Incyte to Report Third Quarter Financial Results (Business Wire)
Sep-29-23 01:43PM	Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress (Business Wire)
Sep-26-23 12:33PM	Unveiling Incyte (INCY)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com)
Sep-21-23 07:11PM	Analyst Report: Incyte Corporation (Morningstar Research)
Sep-20-23 12:12PM	13 Best Beaten Down Stocks To Buy Now (Insider Monkey)
Sep-18-23 04:07PM	Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival (Investor's Business Daily)
11:36AM	Unveiling Incyte (INCY)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com)
09:59AM	FDA approves GSK's unique myelofibrosis treatment Ojjaara (Investing.com)
Aug-31-23 11:31AM	Why Is Incyte (INCY) Down 0.7% Since Last Earnings Report? (Zacks)
Aug-22-23 08:00AM	Incyte to Present at Upcoming Investor Conferences (Business Wire)
Aug-08-23 06:20AM	15 Worst Performing Biotech Stocks in 2023 (Insider Monkey)
Aug-04-23 04:33PM	The Biotech Game Is Changing. Watch for Disruptions, Says RBC. (Barrons.com)
Aug-02-23 07:32PM	Is Incyte (INCY) Modestly Undervalued? A Deep Dive into its GF Value (GuruFocus.com)
Aug-01-23 05:00PM	Analyst Report: Incyte Corporation (Morningstar Research)
10:05AM	Incyte (INCY) Beats on Q2 Earnings and Revenue Estimates (Zacks)
09:30AM	Compared to Estimates, Incyte (INCY) Q2 Earnings: A Look at Key Metrics (Zacks)
08:25AM	Incyte (INCY) Beats Q2 Earnings and Revenue Estimates (Zacks)
08:21AM	Incyte beats estimates on high demand for cancer drug Jakafi (Reuters)
07:17AM	Incyte: Q2 Earnings Snapshot (AP Finance)
07:00AM	Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs (Business Wire)
Jul-31-23 04:01PM	Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma (Business Wire)
09:58AM	Drug, Biotech Stocks' Q2 Earnings Due on Aug 1: PFE, MRK & More (Zacks)
Jul-27-23 10:20AM	Incyte (INCY) to Report Q2 Earnings: What's in the Cards? (Zacks)
Jul-26-23 10:02AM	Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline (Zacks)
Jul-25-23 10:06AM	Disney downgraded, Meta Platforms upgraded: Wall Street's top analyst calls (The Fly)
10:01AM	Earnings Preview: Incyte (INCY) Q2 Earnings Expected to Decline (Zacks)
Jul-24-23 07:00AM	Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease (PR Newswire)
Jul-12-23 12:37PM	Analyst Report: Incyte Corp. (Argus Research)
12:22PM	Market Update: INCY, META (Argus Research)
10:52AM	Incyte's (INCY) Opzelura Meets Goal in Phase III Pediatric Study (Zacks)
Jul-11-23 04:45PM	UPDATE 1-Incyte skin disease cream for children meets main goal in late-stage study (Reuters)
04:19PM	Incyte skin disease drug for children meets main goal in late-stage study (Reuters)
04:05PM	Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis (Business Wire)
08:00AM	Incyte to Report Second Quarter Financial Results (Business Wire)
Jul-05-23 06:12AM	MHRA Grants Marketing Authorisation for Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents (Business Wire)
May-29-23 07:14AM	Shareholders in Incyte (NASDAQ:INCY) are in the red if they invested three years ago (Simply Wall St.)
May-25-23 05:01PM	Data from Across Incytes Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress (Business Wire)
May-23-23 08:00AM	Incyte to Present at Upcoming Investor Conferences (Business Wire)
May-09-23 09:51AM	Q1 2023 Syndax Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
May-08-23 08:30AM	Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role (Business Wire)
May-05-23 03:11AM	4 big analyst cuts: PacWest slashed, stock crashes on sale talks \| Pro Recap (Investing.com)
May-03-23 12:06AM	Q1 2023 Incyte Corp Earnings Call (Thomson Reuters StreetEvents)
May-02-23 04:04PM	Incyte Stock Crumbles As Seasonality Hammers Away At First-Quarter Sales (Investor's Business Daily) -7.14%
03:18PM	Incyte (INCY) Q1 Earnings Miss Estimates, Revenues Up Y/Y (Zacks)
02:21PM	Why Incyte Shares Are Falling Today (Benzinga)
02:04PM	Analyst Report: Incyte Corporation (Morningstar Research)
09:30AM	Incyte (INCY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
09:23AM	Incyte misses quarterly estimates on weak sales of key drugs (Reuters)
08:15AM	Incyte (INCY) Q1 Earnings and Revenues Miss Estimates (Zacks)
07:00AM	Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs (Business Wire)
06:52AM	Is Incyte Corporation (NASDAQ:INCY) Trading At A 49% Discount? (Simply Wall St.)
May-01-23 03:00PM	Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura® (ruxolitinib) Cream (Business Wire)
Apr-27-23 06:10AM	The Zacks Analyst Blog Highlights Biogen, Incyte, Morphic Therapeutic and bluebird bio (Zacks)
Apr-26-23 11:03AM	Will Jakafi Sales Drive a Beat For Incyte (INCY) Q1 Earnings? (Zacks)
10:02AM	Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
07:06AM	Biotech Stock Roundup: BIIB's Q1 Results, ARWR Up on Data, INCY & BLUE Offer Updates (Zacks)
Apr-25-23 10:01AM	Incyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Apr-21-23 12:44PM	Incyte (INCY) Opzelura Gets EC Nod for Non-Segmental Vitiligo (Zacks)
Apr-20-23 10:21AM	Incyte Announces European Commission Approval of Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents (Business Wire)
Apr-19-23 07:22PM	7 Biotech Stocks That Could Cure Your Portfolio Woes (InvestorPlace)
Apr-18-23 08:00AM	Incyte to Present at Upcoming Investor Conferences (Business Wire)
Apr-16-23 03:01PM	MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix) (Business Wire)
Apr-11-23 08:00AM	Incyte to Report First Quarter Financial Results (Business Wire)
Apr-10-23 04:28PM	S&P 500 Stocks: Micron, Charles Schwab Among Top Performers Monday (Investor's Business Daily)
Apr-05-23 04:48PM	Incyte (INCY) Down 9.6% so Far in 2023 on Recent Setbacks (Zacks)
Mar-31-23 10:36AM	The Argus Mid-Cap Model Portfolio (Argus Research)
Mar-29-23 11:24AM	Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback (Zacks)

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SWAIN PAULA J	EVP, Human Resources	Sep 01	Sale	65.13	8,449	550,283	77,530	Sep 06 04:00 PM
Stein Steven H	EVP & Chief Medical Officer	Aug 01	Sale	63.28	21,511	1,361,216	97,583	Aug 03 04:00 PM
BAKER BROS. ADVISORS LP	Director	Mar 13	Option Exercise	22.74	40,000	909,600	33,442,926	Mar 15 04:03 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	Feb 16	Option Exercise	65.42	3,693	241,596	56,956	Feb 21 04:00 PM
Pasquale Maria E	EVP & General Counsel	Jan 31	Option Exercise	74.78	802	59,974	69,326	Feb 02 04:00 PM
Pasquale Maria E	EVP & General Counsel	Jan 31	Sale	84.06	802	67,416	68,524	Feb 02 04:00 PM
Pasquale Maria E	EVP & General Counsel	Jan 30	Option Exercise	73.39	60,024	4,405,224	82,898	Feb 01 04:00 PM
Pasquale Maria E	EVP & General Counsel	Jan 30	Sale	84.74	60,024	5,086,569	68,524	Feb 01 04:00 PM
Iyengar Vijay K	EVP, GMAPPS	Jan 26	Option Exercise	68.62	7,000	480,340	49,835	Jan 30 04:00 PM
Iyengar Vijay K	EVP, GMAPPS	Jan 26	Sale	85.00	7,000	595,000	42,835	Jan 30 04:00 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	Jan 26	Sale	85.00	2,419	205,615	53,263	Jan 30 04:00 PM
Stein Steven H	EVP & Chief Medical Officer	Jan 04	Sale	79.78	28,399	2,265,672	109,021	Jan 06 04:00 PM
Iyengar Vijay K	EVP, GMAPPS	Dec 23	Option Exercise	70.86	14,866	1,053,457	48,179	Dec 28 04:00 PM
Iyengar Vijay K	EVP, GMAPPS	Dec 23	Sale	80.80	17,324	1,399,739	37,855	Dec 28 04:00 PM
Tray Thomas	Principal Accounting Officer	Dec 19	Sale	82.16	1,223	100,482	16,606	Dec 21 04:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INCY

Incyte Corp.

Upgrade your FINVIZ experience